BlueSphere Bio
PrivateLast Round
Series B
Aug 19, 2021
Total Funding Raised
$115M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
BlueSphere Bio operates in Healthcare & Life Sciences and is based in Pittsburgh, Pennsylvania. Its latest recorded funding round was a Series B round in August 2021.
BlueSphere Bio is a biotechnology company that develops personalized T-cell therapies for cancer treatment using its proprietary TCXpress and NeoXPress platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
BlueSphere Bio Comparables
Compare BlueSphere Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| T-Therapeutics | 83% | |
| 3T Biosciences | 82% | |
| Enara Bio | 80% |
For institutional investors. Book with your work email.
BlueSphere Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Aug 19, 2021 | ||||
| Series A | Oct 1, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
BlueSphere Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UPMC Enterprises | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 30% MoM.
- Aug 3, 2026
Open roles increased to 28, 2.1x the trailing average.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventOct 28, 2026
BlueSphere Bio, Inc. CEO Perry Carter delivers the CEO Conclave keynote on advances in breast cancer therapy at MCADDI 2026.
For institutional investors. Book with your work email.
BlueSphere Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about BlueSphere Bio's valuation, stock price, and market status.
Is BlueSphere Bio a public or private company?
BlueSphere Bio is a private company.
What is the current stock price of BlueSphere Bio?
BlueSphere Bio is a private company, so its shares have no public market price. Caplight tracks BlueSphere Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is BlueSphere Bio worth (valuation)?
Valuation information for BlueSphere Bio is not publicly available.
Can I buy BlueSphere Bio stock?
BlueSphere Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was BlueSphere Bio's last funding round?
BlueSphere Bio's most recent funding round was Series B on August 19, 2021.
Who are the main investors in BlueSphere Bio?
Key investors in BlueSphere Bio include UPMC Enterprises.
Will BlueSphere Bio IPO soon?
No public IPO plans have been announced for BlueSphere Bio.
How can I track BlueSphere Bio secondary market activity?
Caplight tracks bids, offers, and trades in BlueSphere Bio's shares on secondary markets.